Barclays Issues Positive Forecast for BeOne Medicines (NASDAQ:ONC) Stock Price

Key Points

• Barclays raised its price target on BeOne Medicines to $446 from $415 and maintained an “overweight” rating, implying about 9.7% upside from the prior close. Analysts overall have a “Moderate Buy” consensus rating and an average target of $432.53.
• BeOne reported quarterly EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion versus estimates of $1.76 billion; the company also raised its 2026 revenue guidance.
• The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma, potentially speeding a decision on expanding the treatment’s use.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price target boosted by analysts at Barclays from $415.00 to $446.00 in a research note issued on Friday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price points to a potential upside of 9.74% from the company's previous close.

A number of other brokerages have also commented on ONC. Nomura lifted their price target on BeOne Medicines from $454.75 to $484.91 and gave the stock a "buy" rating in a report on Thursday, August 6th. Guggenheim upped their price objective on BeOne Medicines from $420.00 to $430.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Royal Bank Of Canada raised their target price on BeOne Medicines from $450.00 to $459.00 and gave the company an "outperform" rating in a research report on Thursday, October 8th. Citizens Jmp lifted their target price on BeOne Medicines from $405.00 to $463.00 and gave the stock a "market outperform" rating in a research note on Friday. Finally, Weiss Ratings upgraded BeOne Medicines from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, BeOne Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $432.53.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock traded up $19.16 during mid-day trading on Friday, hitting $406.41. 409,739 shares of the stock were exchanged, compared to its average volume of 317,660. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $409.80. The company has a 50-day simple moving average of $362.80 and a 200 day simple moving average of $325.98. The company has a market capitalization of $44.62 billion, a P/E ratio of 71.66 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $1.30. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Sell-side analysts anticipate that BeOne Medicines will post 8.99 earnings per share for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 280 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total value of $106,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $357.87, for a total value of $41,158,986.57. Following the completion of the sale, the chief executive officer owned 125,799 shares in the company, valued at approximately $45,019,688.13. The trade was a 47.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 376,373 shares of company stock worth $134,848,154 in the last ninety days. Company insiders own 6.19% of the company's stock.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. boosted its holdings in shares of BeOne Medicines by 184.4% in the third quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company's stock worth $6,660,000 after acquiring an additional 11,800 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new position in shares of BeOne Medicines in the third quarter valued at $106,000. Allspring Global Investments Holdings LLC raised its stake in shares of BeOne Medicines by 22.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company's stock valued at $340,000 after purchasing an additional 178 shares during the period. Hager Investment Management Services LLC bought a new stake in shares of BeOne Medicines during the 3rd quarter valued at $891,000. Finally, Ethic Inc. purchased a new stake in BeOne Medicines during the 3rd quarter worth about $218,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.